Clinical Trials Logo
  1. Home
  2. CADASIL
  3. NCT04658823

Efficacy and Safety of Tocotrienols in CADASIL

Cadasil Clinical Trial

Official title:
A Randomized Placebo-controlled Double-blind Pilot / Phase II Study to Assess the Efficacy and Safety of HOV-12020 in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)

Clinical Trial Summary

CADASIL is a paradigmatic cerebral small vessel disease responsible for white-matter lesions, accumulation of lacunes, microbleeds and cerebral atrophy. The disease is responsible for stroke and cognitive decline associated with motor disability. The number of incident lacunes, and amount of cerebral atrophy were recently found to have a strong relationship to cognitive decline and disability progression over 3 years in a large sample of patients. Palm tocotrienols has previously shown evidence of therapeutic effect in attenuating the progression of WMH related to sporadic cerebral small vessel disease in a randomized controlled clinical trial. We hypothesize that palm tocotrienols complex (HOV-12020) can reduce the clinical progression in CADASIL.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04658823
Study type Interventional
Source Hovid Berhad
Contact
Status Active, not recruiting
Phase Phase 2
Start date December 21, 2020
Completion date December 31, 2023
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03724136 - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study N/A
Recruiting NCT05755997 - CERebrolysin In CADASIL Phase 2
Recruiting NCT06148051 - AusCADASIL: An Australian Cohort of CADASIL
Recruiting NCT04310098 - CADASIL Registry Study
Completed NCT01114815 - Research Study on Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) N/A
Recruiting NCT05677880 - Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
Recruiting NCT02795052 - Neurologic Stem Cell Treatment Study N/A
Completed NCT02837354 - The Silent Cortical Infarcts in the Cerebral Amyloid Angiopathy: Is There a Link With Subarachnoid Hemorrhage? N/A
Recruiting NCT01361763 - Safety Study of Dabigatran in CADASIL Phase 2
Completed NCT02071784 - Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Completed NCT06072118 - Adrenomedullin for CADASIL Phase 2
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Recruiting NCT05473637 - Taiwan Associated Genetic and Nongenetic Small Vessel Disease
Enrolling by invitation NCT02032225 - Generation of a Cellular Model of CADASIL From Skin Fibroblasts N/A
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Withdrawn NCT04334408 - Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL Phase 2
Recruiting NCT05734378 - Prognosis of Cerebral Small Vessel Disease
Recruiting NCT05491980 - Florida Cerebrovascular Disease Biorepository and Genomics Center
Recruiting NCT04036084 - Development of New Biomarkers With Magnetic Resonance Imaging for Longitudinal Studies in CADASIL Angiopathy
Completed NCT01865604 - Impact of tDCS on Cerebral Autoregulation N/A